Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients.
BACKGROUND
Chronic allograft nephropathy (CAN) remains the most common cause of late graft loss especially in sensitized patients. The aim of this study is to evaluate the therapeutic effect of everolimus on cellular and humoral mechanisms of chronic allograft damage in a rat model with sensitized recipients.


METHODS
F344 kidneys were transplanted to LEW.RNU rats. The athymic recipients were reconstituted with 3.5 x 10(7) or 5 x 10(7) presensitized CD4+T-lymphocytes. In the treatment group, everolimus was introduced five weeks posttransplantation. Rats were monitored for peripheral blood lymphocytes, renal function, histological changes in the graft, and the development of donor-specific alloantibodies.


RESULTS
Rats developed cell dose-dependent renal failure. Increased urinary albumin excretion and glomerulopathy were frequently accompanied by the development of donor-specific major histocompatibility complex (MHC) alloantibodies. In the everolimus group, five of six animals survived for 20 weeks with stable serum creatinine and displayed neither acute cellular rejection nor CAN. Prolonged survival was accompanied with significantly reduced tubulointerstitial cell infiltrate in the graft. Increased urinary albumin excretion was present in all, acute tubular necrosis in five of six, and glomerular sclerosis in two grafts. MHC alloantibodies were found in four of six animals.


CONCLUSIONS
The used rat model offers the opportunity to study the influence of everolimus on the interaction of humoral and cellular mechanisms involved in chronic renal damage. Everolimus leads to a prolongation of allograft survival, reduced cell infiltrate in the graft, and prevents tubular atrophy and interstitial fibrosis. The development of alloantibodies and albuminuria was not prevented. These data suggest that although cellular rejection is clearly suppressed, humoral mechanisms of CAN cannot be completely controlled by everolimus treatment in the sensitized rat model.
Koch
Martina
M
Klinik fuer Allgemein-, Viszeral- und Transplantationschirurgie, Medizinische Hochschule Hannover, Germany. koch.martina@mh-hannover.de
Mengel
Michael
M
Poehnert
Daniel
D
Nashan
Bjoern
B
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects*; D002908:Chronic Disease; D004195:Disease Models, Animal; D000068338:Everolimus; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology* / Q000517:prevention & control; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D007150:Immunohistochemistry; D007674:Kidney Diseases / Q000276:immunology* / Q000503:physiopathology / Q000517:prevention & control; D018655:Lymphocyte Count; D008297:Male; D051381:Rats; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology
D000906:Antibodies; D015395:Histocompatibility Antigens Class I; D000068338:Everolimus; D020123:Sirolimus